Danea Horn

This research was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number R01HD0938898. The findings, conclusions, views, and opinions are solely those of the authors and do not necessarily represent the views of the National Institutes of Health, the Federal Trade Commission or any individual commissioner, or the U.S. government.

Danea Horn and Mark Duggan acknowledge research support by the Emerson Collective and the National Institute on Aging 5P01-AG005842-34. Danea Horn was additionally supported by National Human Genome Research Institute R01-HG011792. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.